3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Breast Neoplasms
18
Carcinoma, Renal Cell
8
Neuroendocrine Tumors
6
Tuberous Sclerosis
3
Neoplasm Metastasis
3
Kidney Neoplasms
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Seizures
2
Neoplasms
2
Gastro-enteropancreatic neuroendocrine tumor
2
Carcinoma
2
Carcinoid Tumor
2
Astrocytoma
2
von Hippel-Lindau Disease
1
Unilateral Breast Neoplasms
1
Tuberous Sclerosis Complex-associated Refractory Seizures
1
Tuberous Sclerosis 2
1
Thymus Neoplasms
1
Stomach Diseases
1
Skin Neoplasms
1
Renal Cell Cancer Metastatic
1
Recurrence
1
Prostatic Neoplasms
1
Primary Non-metastatic Breast Cancer
1
Polycystic Kidney, Autosomal Dominant
1
Malignant Carcinoid Syndrome
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Lymphoma
1
Interventions
Everolimus
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Thymus Neoplasms
×
Everolimus
×
Clear all
NCT05918302
2026-05-12
LEVEL
Grupo Espanol de Tumores Neuroendocrinos
Phase 3
Recruiting
170 enrolled